Keystone Symposia: Innate Immune Receptors - Roles in Immunology and Beyond

Immunotherapy has revolutionized the treatment of many cancer types over the past five years. T cell checkpoint inhibitors have led the way and are the focus of most immunotherapy trials. However, innate and non-classical T cells contribute extensively to the tumor infiltrate and significantly affect the tumor immune response both in the tumor microenvironment and in circulation. This symposium aims to bring together academic and industry opinion leaders in the fields of innate immune cells, natural killer cells, tumor microenvironment, tumor immune suppression, novel immunotherapeutic strategies and clinical cancer immunotherapy to define the next wave of immunotherapy breakthroughs that reach beyond the current T cell checkpoints. The conference offers a unique opportunity for an audience of diverse immunology and cancer research backgrounds to come together and share cutting-edge insight into cancer immunology and rational approaches for therapeutic intervention that could be used as stand-alone or in combination with T cell checkpoint therapies.

Topics: immunology, cancer, immunotherapy,